Ascletis BioScience
Company
Ascletis BioScience develops one asset, in phase 3 (denifanstat in acne vulgaris). Mostly small molecule acting on lipid and ceramide metabolism and FASN.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 2
- Signals
Pipeline
1Inhibits fatty acid synthase, reducing de novo fatty acid synthesis.
Phase 3, Small molecule, Lipid and ceramide metabolism, FASN, acne vulgaris, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Signals2
- Similar companies6